Rutinib Cream is a prescription medicine used on the skin (topical) for:
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for:
Ruxolitinib is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Common side effects of Ruxolitinib cream include Nasopharyngitis (3%), Bronchitis (1%), Ear infection (1%), Eosinophil count increased (1%), Urticaria (1%), Diarrhea (1%), Folliculitis (1%), Tonsillitis (1%), Rhinorrhea (1%).
Ruxolitinib inhibits Janus kinase (JAK) pathways, which are involved in transmitting signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function, including inflammation associated with atopic dermatitis. By modulating the JAK signaling pathway, Ruxolitinib prevents the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby reducing inflammation.
Ruxolitinib is contraindicated in patients with known hypersensitivity to the drug or any of its components.
There is no available data on the use of Ruxolitinib in pregnancy and lactation. Therefore, its use should be carefully considered and only used if the potential benefits outweigh the potential risks, as determined by a healthcare professional.
Store below 30°C away from sunlight and keep out of reach of children.